Lauren Walls, PA
Physician Assistant · Wilmington, DENPI 1528510070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $892, 2.4 times the $374 reported in 2021. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$647
- Astellas Pharma US Inc$479
- Bayer$327
- Johnson & Johnson$257
- Ferring Pharmaceuticals Inc.$163
- Teleflex LLC$153
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,07493%
- Education$2467%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 50 | $647 |
| Astellas Pharma US Inc | 23 | $479 |
| Bayer | 16 | $327 |
| Johnson & Johnson | 11 | $257 |
| Ferring Pharmaceuticals Inc. | 10 | $163 |
| Teleflex LLC | 4 | $153 |
| Tolmar, Inc. | 6 | $126 |
| Pfizer | 7 | $106 |
| Myovant Sciences Inc. | 6 | $103 |
| Myriad Genetic Laboratories, Inc. | 4 | $102 |
| AbbVie | 5 | $94 |
| Merck | 3 | $64 |
| Tempus AI, Inc | 2 | $55 |
| Axonics, Inc. | 2 | $54 |
| Novartis | 2 | $53 |
| Antares Pharma, Inc. | 3 | $52 |
| Urogen Pharma, Inc. | 2 | $52 |
| Palette Life Sciences, Inc. | 1 | $52 |
| Tolmar Pharmaceuticals, Inc. | 2 | $46 |
| Accord Healthcare, Inc. | 2 | $40 |
| Dendreon Pharmaceuticals LLC | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Foundation Medicine, Inc. | 1 | $30 |
| Blue Earth Diagnostics | 1 | $29 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Rochester Medical Corporation | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Immunitybio, Inc. | 1 | $16 |
| Eagle Pharmaceuticals, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $11 |
How this compares
$3,320 in reported general payments places this provider in the 90th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 160 | $185,120 |
| MyrbetriqMirabegron | 175 | $161,635 |
| Tamsulosin Hcl | 664 | $14,922 |
| PremarinEstrogens, Conjugated | 13 | $5,461 |
| Estradiol | 78 | $5,276 |
| Testosterone | 19 | $4,432 |
| Methenamine Hippurate | 28 | $3,111 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,743 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 70 | $2,563 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 129 | $2,340 |
| Testosterone Cypionate | 56 | $2,066 |
| Solifenacin Succinate | 30 | $1,499 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 80 | $1,117 |
| Cefpodoxime Proxetil | 41 | $901 |
| Finasteride | 57 | $875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $647 | $185,120160 claims |
| Astellas Pharma US IncMyrbetriq | $479 | $161,635175 claims |
| PfizerPremarin | $106 | $5,46113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Wilmington
- Jason SaulWilmington$9K
- Brooke EnderleWilmington$7K
- Matthew StumpWilmington$5K
- Christopher HoverWilmington$5K
- Julie SimsWilmington$5K
- Joan TaddeiWilmington$4K
- Gabriel PelaezWilmington$4K
- Caitlin McCarryWilmington$4K
- Samantha DelfeldWilmington$4K
- Shannon MohollenWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.